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Purpose: To synthesize and characterize the dextran conjugates of suprofen and flurbiprofen, and also 
evaluate their biological activities.  
Methods: Suprofen and flurbiprofen were individually reacted with carbonyldiimidazole to form 
acylimidazole, which, in turn, was reacted with the dextran of varying molecular weight (40 000, 60 000, 
and 110 000) to form drug-dextran conjugates. The structures of the synthesized dextran conjugates 
were confirmed by IR and NMR spectroscopy. In vitro hydrolysis of the conjugates were studied in buffer 
solutions (pH 7.4 and 9.0) and 80% human plasma (pH 7.4). The analgesic and antipyretic activities, as 
well as the ulcerogenic index of the conjugates were also evaluated in albino rats. 
Results: The mean degree of substitution of flurbiprofen and suprofen was between 8.0 to 9.5 % and 
7.5 to 9.0 %, respectively. In vitro hydrolysis studies on the conjugates indicate faster hydrolysis at pH 
9.0 than in pH 7.4 buffer solution and 80% human plasma (pH 7.4) with the process following First order 
kinetics. The analgesic activity of flurbiprofen-dextran conjugate (FD-110) suprofen-dextran conjugate 
(SD-110) was 64.23 and 41.50% which  compare well with those of their parent drugs - flurbiprofen 
(72.60%) and suprofen (44.30%). Similar findings were made in respect of the antipyretic activity. Both 
flurbiprofen and suprofen showed deep ulceration, swelling and high intensity perforation in the gastric 
mucosa after seven days administration of flurbiprofen and suprofen with the ulcerogenic indices of 
29.69 and 31.0 respectively, cpmpare with 5.88 and 6.06 for FD-110 and SD-110, respectively.  
Conclusion: Dextran can be employed as a pro-moiety or carrier for the delivery of flurbiprofen and 
suprofen and showed comparable analgesic and antipyretic activities with the parent drugs but with 
lower ulcerogenic indices. 
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Not too long ago, polymeric prodrug 
conjugates were ushered into the era of 
polymeric drug delivery. The task of obtaining 
a versatile polymer as an ideal candidate in 
drug delivery can be intricate since it has to 
surmount several vigorous clinical barriers
1
.  
Dextran has excellent physicochemical 
properties and physiological acceptance such 
as the capacity to be stored in depots, unique 
pharmacokinetic profiles, potential body 
distribution and pharmacological efficacy
2,3
. 
The literature reveals that in most of the 
macromolecular or polymeric prodrug 
approaches, the drug is either linked by 





Nonsteroidal anti-inflammatory drugs are 
among the most frequently used groups of 
drugs to treat the disorders caused by 
inflammation
11-13
. The phenyl propionic acid 
derivatives such as flurbiprofen {2-(3-fluoro-4-
phenyl-phenyl) propanoic acid} and suprofen 
{2-(4-(thiophene-2-carbonyl) phenyl) 
propanoic acid} possess analgesic and 




however, they also possess certain 
undesirable gastro-intestinal (GI) side effects 
such as gastric ulceration and hemorrhage 
which are attributed in part to the presence of 
an acidic group, and this can be masked 
temporarily by conjugating with a biopolymer 
dextran. Previously, we synthesized and 
evaluated dextran conjugates of flurbiprofen 
and suprofen for their anti-inflammatory 
action
19,20
. In this study, the dextran 
conjugates of flurbiprofen (FD) and suprofen 
(SD) were prepared with the intention of  
achieving reductions of GI side-effects while 
retaining their analgesic and antipyretic 
activities. 
MATERIALS AND METHODS 
 
Materials and equipment 
 
Flurbiprofen and suprofen powders were 
obtained as gifts from Cipla Ltd, Mumbai, 
India. Dextran (molecular weight - 40 000, 60 
000 and 1 10 000) and N, N
1
–
carbonyldiimidazole (CDI) were purchased 
from Sigma-Aldrich Chemicals Ltd, USA. 
Silica gel G for TLC and solvents for HPLC 
analysis were purchased from Merck India. All 
other solvents and chemicals were of reagent 
grade and obtained from Qualinges fine 
chemicals, Mumbai.  
 
Ultra-violet spectra of the synthesized 
conjugates were generated using Shimadzu 
160-A, UV/Visible Spectrophotometer. In vitro 
hydrolysis of SD and FD conjugates was 
performed using a water-HPLC system 
(Rexdale, Canada) consisting of a model 
6000A pump, a 710 B WISP auto injector, and 
a 490 multiple-wave length UV detector 
operated at ambient temperature. Separation 
was carried out on octadecyl-bonded silica 
(5µm, ODS-3) stainless steel column (10 x4.6 
mm, i.d.) along with a 5 cm guard column of 
the same material and particle size 10 µm. 
The mobile phase composition for separation 
was acetonitrile: water: phosphoric acid in the 
ratio 45:54:1 v/v and acetonitrile: 0.67 M 
KH2PO4: triethylamine in the ratio 35: 65: 0.02 
v/v, respectively, for SD and FD conjugates. 
The flow rate was maintained at 1.0 ml/min. 
 
The infrared spectra were recorded on 
Shimadzu 8300 FT-IR spectrophotometer 
using KBr pellets in the range 4000 to 400/cm. 
1
H NMR spectra were obtained on a Bruker 
DRX -NMR spectrophotometer operating at a 
frequency of 300 MHZ in DMSO-d6. 
 
Synthesis of dextran conjugates 
 
Dextran conjugates of flubriprofen and 
suprofen were prepared by first activating the 
carboxylic group using CDI to obtain 
flubriprofen and suprofen acylimidazole (FAI 
and SAI)
 21
 which were then condensed with 
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dextran of different molecular weight (40 000, 
60 000, and 110 000) in situ to get FD-40, FD-
60, FD-110 and SD-40, SD-60, SD-110, 
respectively, as shown in Scheme 1. The 
progress of the reaction was monitored by thin 
layer chromatography, which was performed 
on silica gel (Merck No. 5554) as stationary 
phase and chloroform: methanol (7:3) as 
mobile phase. N, N – carbonyl diimidazole 
(CDI) is moisture-sensitive and, therefore, dry 
solvents were used throughout and anhydrous 
conditions were maintained during the 
experiment. 
 
The IR and NMR spectral data of  FD 
conjugates; IR (KBr, νmax cm
-1
):  1728.7 
(C=O str.), 2963 (aromatic str.), 736 (C-H 
aromatic bending), 3400-3278 (-OH str.of 
polymeric -OH dextran), 1568.(str. of biphenyl 
ring), 1010 (C-F str.) 
1
H NMR (DMSO d6, 
ppm): 7.27- 7.52 (m, 8H, aromatic ring), 3.89 
(q, 2H, -CH2),  1.46 (t, 3H, -CH3), 5.30-3.63 
(m, anomeric protons of  glucosidic ring), 2.0-
2.49 (-OH of dextran monomer). The IR and 
NMR spectral data of SD conjugates; IR (KBr, 
νmax cm
-1
):  1723.6 (C=O str.), 2918 
(aromatic str.), 742 (C-H aromatic bending), 
3400-3243 (-OH str.of polymeric -OH 
dextran), 2970 (C-H str. of alkene), 1025 
(thienyl str.), 1350 (C-S str.)  
1
H NMR (DMSO 
d6, ppm): 7.6- 8.0 (m, 4H, aromatic ring), 7.29- 
7.55 (m, 3H, thiophene ring), 3.94 (q, 2H, -
CH2), 1.23 (t, 3H, -CH3), 5.32-3.44 (anomeric 







The degree of substitution of flurbiprofen and 
suprofen was determined by dissolving 20 mg 
of the dextran conjugate in 20 ml solution of 
phosphate buffer (pH 9.0). The reaction 
mixture was maintained at 70
°
C for one hour 
and left for 24 h for complete hydrolysis. It 
was then neutralized with 1N HCl. The 
amount of flurbiprofen and suprofen drugs 
released due to hydrolysis was extracted with 
chloroform and determined by HPLC at the 
absorption maxima of 248.4 nm and 296 nm 
respectively
22,23
. In vitro hydrolysis of dextran 
conjugates was determined by HPLC using 
the mobile phase indicated earlier. The 
amount of hydrolyzed dextran conjugates was 
derived from the measurement of the peak 
area in relation to those of the standard drug 
response under same conditions. 
 
Molecular weight determination 
 
The molecular weight of the conjugates was 




correlates molecular weight and intrinsic 
viscosity.  
[η] = k M
α
    ……………….……….   (1) 
 
where [η] is the intrinsic viscosity, M is the 
molecular weight, and k and α are constants 
having values 7.24×10
-4
 (dl/g) and 0.52 
respectively. The values were determined by 
plotting ηsp/ C against C. Molecular weight 
was then calculated using the above equation. 
 
In vitro hydrolysis 
 
In-vitro hydrolysis of the dextran conjugates 
was studied in different phosphate buffer 
solutions (pH 7.4 and 9.0 and 80% human 
plasma pH 7.4) and the rate of hydrolysis of 
the dextran conjugates was computed as the 
percent drug hydrolysed based on the 
cumulative amount of drug hydrolysed divided 
by the total amount of drug contained in the 
conjugate. The rate of hydrolysis and half-life 













2/1 = ……….……………..          (3) 
where k is the rate constant, t is the time in 
hours, a is the initial concentration of 
conjugate, x is the amount of the conjugate 
hydrolyzed into the free drug, a-x is the 
amount of drug remaining in conjugated form 
and t½ is the half life of conjugate. 
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Table 1:   Degree of substitution (DS) and molecular weight (Mw) of flurbiprofen- and  suprofen dextran 
conjugates 
 
S/no. Dextran conjugate DS
a
























  112082 
48400 
72000 
  129600 
 52900 
 67600 
  122500 
a = amount of parent drug in mg per 100 mg of conjugate 
 
 
Table 2:  Hydrolysis data for dextran conjugates in phosphate buffer human plasma at 37 ± 0.5 ºC 
 
  Dextran         Half-life (t½)
a
 of dextran conjugates (hr
-1
) 
  Conjugate                                     pH 7.4              pH 7.4   pH 9.0 
(80% human plasma) 
 
     FD-40   13.81              12.77   0.98 
     FD-60   17.65             15.71   1.07 
     FD-110   21.17             21.34   1.13 
     SD-40                 47.80             36.64     3.55 
     SD-60                 49.14             45.23     3.60 
     SD-110                   52.90             46.10    3.96 
a = Average half-life of four trials. 
Table 3: Analgesic activity of the parent drugs and their dextran conjugates 
 
Test Compound    Oral dose           % Analgesic activity at different time (min) 
         (mg/kg)     
   15       30           45          60   75    90          120 
Flurbiprofen       2.00         18.30       30.08        41.60        61.60           70.00         72.60     65.56 
FD-40          21.05               07.25      20.00        31.20        40.74            53.40        58.24     51.23 
FD-60           22.20 10.50   24.13        33.60        44.80     55.30        61.40     57.14 
FD-110           23.52  12.06   26.50        35.10        48.70     58.60       64.23      60.50 
Suprofen       5.00  15.20   23.72      28.81       36.00     40.60       44.30   42.60 
SD-40        55.55  05.76   11.53        23.07       28.84     35.30       38.46   36.20 
SD-60         59.52   07.14   16.07     25.00       33.00     36.00  40.30      38.60 
SD-110           62.50   08.70   19.80       27.60       34.00     38.00  41.50   40.00 
 
FD: Flurbiprofen-dextran conjugate      SD: Suprofen-dextran conjugate    Number of animal in each group six             
Statistical significance p < 0.05 in relation to control 
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Table 4 Antipyretic activity
a
 and ulcerogenic index of the parent drugs and their dextran conjugates 
 
     Test                Oral dose  Antipyretic activity (ºF)       Ulcerogenic 
Compound      (mg/kg)          Mean ± S.E.            Index   
                                    0 hr           1 hr         2 hr    3 hr           4 hr          (UI)      
 
Flubriprofen       2.00            101.6      101.1         99.9            99.1          98.5  
                            ±              ±               ±               ±               ±                 29.69 
                                                     0.197      0.507          0.741          0.90          0.93  
 
FD-40            21.05           99.2        98.7           98.2            97.4           97.1 
                                                       ±             ±                ±                  ±               ±               9.16                    
                                                     0.458      0.354          0.466          0.50         0.467 
 
FD-60                                   22.2             99.5         99.0           98.6            98.3          97.8   
                                                       ±             ±                ±                  ±              ±                7.06 
                                                     0.401      0.120          0.330          0.466        0.433 
 
FD-110                               23.52           100.1        99.5          98.8             98.4          98.0 
            ±              ±   ±                 ±                ±              5.88 
                                                     0.499      0.166          0.387           0.578        0.619 
 
Suprofen     5.00             102.1      101.2          100.8            99.6         99.0 
            ±            ±                   ±                ±              ±             31.0 
          0.456      0.542          0.691           0.882        0.936 
 
SD-40        55.55           99.6        99.1            98.5             96.8         96.1 
                                                  ±             ±                ±                   ±              ±             9.83  
                0.636      0.381         0.456            0.555       0.562 
 
SD-60     59.52            100.1       99.8           99.1             98.2         97.3 
                                                    ±              ±               ±                 ±              ±             9.90 
                                              0.199      0.136          0.381           0.542        0.477 
 
SD-110                           62.50           100.8       100.2          99.6             99.0         98.4 
                                                       ±               ±      ±                 ±              ±               6.06 
                                                    0.552      0.155           0.385           0.675        0.610 
 
FD: Flurbiprofen-dextran conjugates; SD: Suprofen-dextran conjugates; 
a
Number of animal in each  
group six; p < 0.05 in relation to control (One-way ANOVA) 
    
 




Analgesic activity was evaluated by the tail-
flick method of Davies et al
 25
 using Techno-
analgesiometer (Inco, Ambala, India).  The 
suspension of drug or drug conjugate was 
prepared in 2% gum acacia. Ten experimental 
groups of albino rats, each having six rats 
weighing between 100-150 g were taken and 
the radiant heat from the wire was passed 
onto the tail, which was placed on the bridge 
of the analgesiometer. After recording the 
normal reaction time, the reaction time for tail-
flick response was determined in different 
groups of rats by administering the test 
compounds orally at 15 min interval over a 
period of 120 min. The analgesic activity of 
these compounds was calculated using the 
following formula:   
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Scheme 1: Drug dextran conjugate synthesis 
 
 
% analgesia = [1-t2/ t1] x 100   …..……….   (4) 
 
where, t1 = reaction time (sec) before drug 
administration and t2 = reaction time (sec) 




The antipyretic activity was evaluated by the 
method of Niemegeers et al and Teotino et al 
in which ten experimental groups of albino 
rats each having six animals were induced 
pyrexia by injecting a suspension of 15 % 
dried Brewer’s yeast in 2% gum acacia in 
normal saline subcutaneously and the 
stabilized temperature was recorded after 18 
hr. The test compounds were then 
administered orally to the rats and the rectal 







The ulcerogenic index was determined by the 
method of Khan and Khan
28
 and as previously 




 Wistar rats 
were randomly assigned to control and 
experimental groups, with six rats in each 
group. The suspension of the drug and its 
dextran conjugates in 2% gum acacia 
mucilage was administered orally to the rats 
for seven days. The rats were fasted for 8 h 
prior to dosing and 4 h post-dosing and then 
sacrificed. The abdomen was opened at the 
mid-line, and the stomach as well as the first 3 
cm of the duodenum were removed. The 
stomach was opened along the greater 
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curvature and washed with saline water. The 
mucus was wiped off and observed for ulcer in 
the glandular portion of the stomach. The 
number of ulcer spots was noted and the 
severity of ulcer was scored by means of 
magnifying lens (10 X). The ulcerogenic index 
(UI) of these compounds was computed using 





Ulcerogenic index = number of ulcers + ulcer 




IR and NMR data 
 
The IR spectra of flurbiprofen and suprofen 
dextran conjugates showed a characteristic 
absorption stretching at 1720-1730 cm
-1 
which 
confirms an ester linkage. A strong O-H 
stretching vibration of polymeric association at 
3400-3200 cm
-1
 and a weak C-H stretching of 
alkene at 2970 cm
-1 
was found in both types of 
conjugates. FD conjugates showed 





 for biphenyl and C-F, 




was observed for thienyl and 





NMR spectra showed a characteristic shifting 
of glucosidic ring anomeric proton signals 
from δ 4.91 (d, 1H, H-1) to δ   5.2 (s, 1H, H-1) 
and H-2 proton from δ  3.42 (m, 1H, H-2) to 
δ 3.89 (s, 1H, H-2) for FD, while the shifting of 
glucosidic ring anomeric proton signals from 
δ 4.91 (d, 1H, H-1) to δ 5.17 (s, 1H, H-1) and 
H-2 proton from δ 3.42 (m, 1H, H-2) to δ 3.94 
(s, 1H, H-2) for SD indicates the formation of 
ester linkage at C-2 position of glucosidic ring. 
The disappearance of 
1
H NMR signals in the 
range of 10.86-11.25 ppm for carboxylic group 
in all the drug-dextran conjugates suggests 
that the free carboxylic group of drug was 
conjugated with hydroxyl group of  dextran 
macromolecule and formed the ester bond. 
The signals of biphenyl aromatic ring of 
flurbiprofen and thienyl carbonyl benzene ring 
of suprofen were found to be δ 7.27-7.52 (m, 
8H, aromatic ring) and δ 7.29-8.0 (m, 7H, 
aromatic ring and thiophene ring) for FD and 
SD, respectively, which were in agreement 




Degree of substitution and hydrolysis 
 
The degree of substitution of flurbiprofen and 
suprofen was found to be between 8.0 to 9.5 
% and 7.5 to 9.0 % respectively. The 
molecular weights of the conjugates are 
summarized in Table 1. The results of in-vitro 
hydrolysis studies in solutions of different 
phosphate buffer medium i.e., pH 7.4, 9.0 and 
80% human plasma (pH 7.4) at 37 ± 0.5 ºC 
are shown in Table 2 and they indicate a slow 
rate of hydrolysis at pH 7.4 and relatively 
faster hydrolysis at pH 9.0. Hydrolysis 




The maximum analgesic activity of 
flurbiprofen, suprofen and their dextran 
conjugate were observed after 75 and 90 min, 
respectively. The percent analgesic activity of 
FD-110 (64.23) and SD-110 (41.50) were 
identical to those of their parent drugs - 
flurbiprofen (72.60) and suprofen (44.30). The 
antipyretic activity of flurbiprofen and suprofen 
dextran conjugates were also comparable with 
those of their parent drugs. The results are 
summarized in Table 3 and 4.  
 
It was observed that parent drugs, flurbiprofen 
and suprofen, showed deep ulceration, 
swelling and high intensity perforation in the 
gastric mucosa after a seven-days 
administration ulcerogenic index of 29.69 and 
31.0, respectively. On the other hand, the 
conjugates, FD-40 and FD-60, showed 
ulcerogenic index of 9.16 and 7.06, 
respectively but in the case of FD-110, only 
oedematous gastritis with a much lower 
ulcerogenic index of 5.88 was observed. The 
suprofen conjugates were also showed similar 
pathological changes as flurbiprofen. SD-40 
and SD-60 showed more ulcers in gastric 
mucosa with ulcerogenic index of 9.83 and 
9.90, respectively. The ulcerogenic index 
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observed for SD-110 was 6.06. All the results 
of biological evaluation were statistically 





The dextran conjugates of flurbiprofen and 
suprofen were synthesized using N, N’ 
carbonyldiimidazole which reacts with the free 
acidic group of the drug to form active 
acylimidazole. The acylimidazole active 
moiety condensed with the hydroxy group of 
dextran to form ester conjugates. The purity of 
synthesized conjugates was confirmed by 
TLC which showed different Rf values of 
conjugates from the drug substance. The 
characteristic band in IR spectra was obtained 
which confirmed the formation of ester bond 
between the free acidic groups of drug and 
the hydroxy group of the dextran molecule. 
1
H 
NMR spectra showed disappearance of acidic 
proton and characteristic shifting of anomeric 
proton signals which indicates the formation of 
an ester linkage at C-2 position. It was also 
observed that the molecular weight of dextran 
increased as the degree of substitution is 
decreased. The hydrolysis study indicate that 
ester conjugates of dextran showed greater 
specific base catalytic hydrolysis at pH 9.0 
and this may be attributed to the basic 
character of the carbohydrate alkoxide ion. 
The increased tendency of these dextran 
derivatives to undergo hydrolysis in the pH 
range 6 to 10 may be due to intermolecular 
catalysis by the neighboring hydroxy group. 
The rate data for hydrolysis of flurbiprofen and 
suprofen dextran conjugates at different pH 
and 80% human plasma was high which 
indicates that the hydrolysis reaction in 
plasma may have been affected by enzymatic 
interference. The hydrolytic regeneration of 
flurbiprofen and suprofen from the conjugates 
was studies in the different buffers followed 
first order kinetics. The half-life of the 
conjugates was higher in pH 7.0 and human 
plasma (pH 7.0) than in pH 9.0 buffer solution 
which suggests that the drugs would be 
absorbed faster at pH 9.0. 
 
The analgesic and antipyretic activities of 
flurbiprofen and suprofen dextran conjugates 
were comparable to those of their parent 
drugs. While flurbiprofen and suprofen 
showed deep ulceration, swelling and high 
intensity perforation in the gastric mucosa 
after seven days, the dextran conjugates of 
the drugs manifested oedematous congestion, 
hemorrhagic gastric mucosa and negligible 
ulcers. SD-40 and SD-60 conjugates showed 
more ulcers in the gastric mucosa than SD-
110 and this may be due to the chemical 
nature of carrier drug linkage. 
 
 The results shows that the molecular weight 
of dextran play an important role in ulcer 
activity, in that as the molecular weight of 





Data obtained from hydrolysis, UV, HPLC, FT-
IR, and 
1
H NMR studies and molecular weight 
determination demonstrated that dextran can 
be successfully employed as pro-
moiety/carrier for flurbiprofen and suprofen 
which have an acidic function. The resulting 
conjugates retained the analgesic and 
antipyretic activities of the parent compunds 
and also showed remarkable reductions in 
ulcerogenicity when compared with their 
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